文献速递关节外科

2019年John Insall奖:果糖胺在预测全膝关节置换术后不良结局方面优于糖化血红蛋白(HbA1c):一项前瞻性多中心研究

2019 John Insall Award: Fructosamine is a better glycaemic marker compared with glycated haemoglobin (HbA1C) in predicting adverse outcomes following total knee arthroplasty: a prospective multicentre study.
PubMed 文献 · Bone Joint J · 2019-01-01

该前瞻性多中心研究纳入四个学术机构的1119例初次全膝关节置换术患者,评估果糖胺与糖化血红蛋白(HbA1c)预测术后12周并发症的效用。果糖胺293 µmol/l为最佳截断值,高于此值的患者假体周围感染、再入院和再手术风险显著升高,而HbA1c的三个截断值均与并发症无显著关联。结论认为果糖胺是预测全膝关节置换术后并发症的有效指标,优于HbA1c。

要点

  • 果糖胺293 µmol/l是预测全膝关节置换术后并发症的最佳截断值。
  • 果糖胺高于293 µmol/l者假体周围感染风险为低果糖胺者的11.2倍(p=0.001)。
  • HbA1c的7%、7.5%及Youden指数确定的截断值均与并发症无显著关联。

核心结论

  • 果糖胺是全膝关节置换术后并发症的有效且优良的预测指标,比HbA1c更好地反映血糖控制、对不良事件有更强的预测能力且对治疗反应更快。
  • 这些发现支持对所有接受全膝关节置换术的患者进行果糖胺筛查,对于果糖胺水平高于293 µmol/l的患者,应仔细权衡手术风险与获益。

研究设计与样本

  • 前瞻性多机构研究,评估来自四个学术机构的初次全膝关节置换术患者(包括糖尿病患者和非糖尿病患者)。
  • 在手术前30天内检测果糖胺和HbA1c水平,术后12周内评估并发症,包括假体周围感染、伤口并发症、再入院、再手术和死亡。
  • 使用Youden指数确定与并发症相关的果糖胺和HbA1c截断值,并额外检查HbA1c的7%和7.5%两个截断值。
  • 共纳入1119例患者(441例男性,678例女性)。

主要发现

  • 果糖胺293 µmol/l被确定为与并发症相关的最佳截断值。
  • 果糖胺高于293 µmol/l的患者发生假体周围感染的可能性是低果糖胺患者的11.2倍(p=0.001)。
  • 果糖胺高于阈值的患者再入院率和再手术率分别高出4.2倍和4.5倍(p=0.005和p=0.019)。
  • 果糖胺升高组有1例患者(1.7%)死亡,而果糖胺正常组有1例患者(0.1%)死亡(p=0.10)。
  • 这些并发症在多元回归分析中仍具有统计学显著性。

关键数值与推荐

  • 果糖胺最佳截断值:293 µmol/l。
  • 果糖胺高于293 µmol/l者假体周围感染风险为低果糖胺者的11.2倍(p=0.001)。
  • 果糖胺高于293 µmol/l者再入院率为低果糖胺者的4.2倍(p=0.005),再手术率为4.5倍(p=0.019)。
  • 果糖胺升高组死亡率1.7%(1例),果糖胺正常组死亡率0.1%(1例),p=0.10。
  • HbA1c截断值7%、7.5%及Youden指数确定的截断值均与并发症无显著关联。

临床怎么用

  • 作者认为这些发现支持对所有接受全膝关节置换术的患者进行果糖胺筛查。
  • 作者认为对于果糖胺水平高于293 µmol/l的患者,应仔细权衡手术风险与获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The best marker for assessing glycaemic control prior to total knee arthroplasty (TKA) remains unknown. The purpose of this study was to assess the utility of fructosamine compared with glycated haemoglobin (HbA1c) in predicting early complications following TKA, and to determine the threshold above which the risk of complications increased markedly. PATIENTS AND METHODS: This prospective multi-institutional study evaluated primary TKA patients from four academic institutions. Patients (both diabetics and non-diabetics) were assessed using fructosamine and HbA1c levels within 30 days of surgery. Complications were assessed for 12 weeks from surgery and included prosthetic joint infection (PJI), wound complication, re-admission, re-operation, and death. The Youden's index was used to determine the cut-off for fructosamine and HbA1c associated with complications. Two additional cut-offs for HbA1c were examined: 7% and 7.5% and compared with fructosamine as a predictor for complications. RESULTS: Overall, 1119 patients (441 men, 678 women) were included in the study. Fructosamine level of 293 µmol/l was identified as the optimal cut-off associated with complications. Patients with high fructosamine (> 293 µmol/l) were 11.2 times more likely to develop PJI compared with patients with low fructosamine (p = 0.001). Re-admission and re-operation rates were 4.2 and 4.5 times higher in patients with fructosamine above the threshold (p = 0.005 and p = 0.019, respectively). One patient (1.7%) from the elevated fructosamine group died compared with one patient (0.1%) in the normal fructosamine group (p = 0.10). These complications remained statistically significant in multiple regression analysis. Unlike fructosamine, all three cut-offs for HbA1c failed to show a significant association with complications. CONCLUSION: Fructosamine is a valid and an excellent predictor of complications following TKA. It better reflects the glycaemic control, has greater predictive power for adverse events, and responds quicker to treatment compared with HbA1c. These findings support the screening of all patients undergoing TKA using fructosamine and in those with a level above 293 µmol/l, the risk of surgery should be carefully weighed against its benefit. Cite this article: Bone Joint J 2019;101-B(7 Supple C):3-9.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Shohat N, Tarabichi M, Tan TL, et al. 2019 John Insall Award: Fructosamine is a better glycaemic marker compared with glycated haemoglobin (HbA1C) in predicting adverse outcomes following total knee arthroplasty: a prospective multicentre study. Bone Joint J. 2019. PMID: 31256656. doi:10.1302/0301-620X.101B7.BJJ-2018-1418.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。